Viewing Study NCT00905593


Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2025-12-26 @ 6:07 AM
Study NCT ID: NCT00905593
Status: APPROVED_FOR_MARKETING
Last Update Posted: 2012-07-18
First Post: 2009-05-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module